论文部分内容阅读
目的:观察利妥昔单抗联合GDP方案治疗复发难治性弥漫大B细胞淋巴瘤(DLBCL)的疗效和不良反应。方法:2009-01-2013-12在我院住院的复发难治性DLBCL患者28例,采用利妥昔单抗联合GDP方案化疗(利妥昔单抗375mg/m2 d0,吉西他滨1 000mg/m2 d1、8,顺铂25mg/m2 d1~3,地塞米松40mg/d d1~4),21d为一个疗程。完成2个疗程后评价疗效及不良反应。结果:随访9~58个月,28例患者中13例获得完全缓解,9例获得部分缓解,1例疾病稳定,5例疾病进展,总有效率为78.6%;常见的不良反应为骨髓抑制和胃肠道反应。结论:利妥昔单抗联合GDP方案是治疗复发难治性DLBCL一个安全有效的挽救方案。
Objective: To observe the efficacy and side effects of rituximab combined with GDP regimen in the treatment of recurrent refractory diffuse large B cell lymphoma (DLBCL). METHODS: Twenty-eight patients with relapsed and refractory DLBCL hospitalized in our hospital from January 2009 to December 2013 were treated with rituximab combined with GDP regimen (rituximab 375mg / m2 d0, gemcitabine 1 000mg / m2 d1 , 8, cisplatin 25mg / m2 d1 ~ 3, dexamethasone 40mg / d d1 ~ 4), 21d for a course of treatment. After completion of 2 courses evaluation of efficacy and adverse reactions. Results: During the follow-up period of 9-58 months, 13 of 28 patients achieved complete remission, 9 achieved partial remission, 1 had stable disease and 5 had progressive disease with a total effective rate of 78.6%. The common adverse reactions were bone marrow suppression Gastrointestinal reaction. Conclusions: Rituximab combined with GDP regimen is a safe and effective salvage plan for relapsed and refractory DLBCL.